J&J Builds Caplyta's Bipolar Treatment Potential with Trial Win

Johnson & Johnson (J&J) has taken another significant step in expanding Caplyta’s bipolar treatment potential, securing its second positive Phase 3 trial result for bipolar mania.

The latest findings strengthen the drug’s prospects for a broader role in managing bipolar I disorder and bring the company closer to a planned US Food and Drug Administration (FDA) submission.

The development also creates an opportunity for J&J to expand its neuroscience portfolio and strengthen Caplyta’s commercial position. The trial success further reinforces Caplyta’s potential to address unmet needs in bipolar mania while supporting J&J’s long-term growth ambitions in neuroscience.

Second Phase 3 Trial Strengthens Caplyta’s Bipolar Mania Case

J&J evaluated Caplyta 42 mg once daily against placebo over three weeks in adults experiencing manic episodes, with or without mixed features, associated with bipolar I disorder. The second late-stage study delivered encouraging clinical results:

• Patients receiving Caplyta showed a 3.7-point greater reduction in mania scores than those receiving placebo at Week 3.
• Clinical improvements emerged as early as Day 3.
• Nearly 44% of Caplyta-treated patients achieved at least a 50% improvement in mania symptoms, compared with approximately 24% in the placebo group.

These findings build on the first successful Phase 3 trial and provide J&J with consistent clinical evidence to support its planned FDA submission. The results strengthen Caplyta’s potential in bipolar treatment by demonstrating improvements across two late-stage studies.

Also Read: 10 Health Habits Doctors Swear By but Rarely Talk About

Caplyta Expansion Could Strengthen J&J’s Neuroscience Portfolio

Caplyta already holds US approval for bipolar depression, schizophrenia and certain cases of major depressive disorder. An additional indication for bipolar mania could extend its reach across both depressive and manic episodes associated with bipolar I disorder.

J&J gained access to the drug through its USD 14.6 billion acquisition of Intra-Cellular Therapies in 2025, strengthening its neuroscience business. The proposed expansion could further enhance the drug’s commercial value.

UBS analysts project substantial growth opportunities for Caplyta, estimating:

• Long-term peak sales potential above USD 5 billion.
• Approximately USD 4.3 billion in sales by 2033.

With two positive Phase 3 studies, J&J has strengthened its bipolar treatment ambitions and commercial outlook. The planned FDA submission now represents the next major milestone, although regulatory approval for bipolar mania remains pending.